Spyre Therapeutics Inc (SYRE) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
R&D Expenses : Increased to $33.7 million in Q4 2023 from $14.3 million in Q4 2022, reflecting investment in IBD pipeline. G&A Expenses : Rose to $14.1 million in Q4 2023, up from $5.1 million in Q4 2022, due to stock compensation and professional service fees. Net Loss : Reported at $63.2 million for Q4 2023, including non-cash stock compensation expense of $17.3 million. Corporate Updates : Appointment of new CEO, Board members, and $180 million raised in private placement. Development Pipeline : Progress on preclinical programs, with first-in-human studies for SPY001 and SPY002 expected in 2024. Warning! GuruFocus has detected 5 Warning Signs with SYRE. On February 29, 2024, Spyre Therapeutics Inc ( NASDAQ:SYRE ), a biotechnology company focused on developing innovative therapies for inflammatory bowel disease (IBD), released its 8-K filing , detailing the fourth quarter and full year financial results for 2023. The company, which recently underwent a corporate name ch
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsPR Newswire
- Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Wells Fargo & Company from $35.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at BTIG Research from $32.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 5/9/24 - Miss
SYRE
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- SYRE's page on the SEC website